Nasal Vaccine for Alzheimer’s Disease Enters Clinical Trial
In November 2021, Brigham and Women’s Hospital in Boston launched the first human trial of a nasal vaccine for Alzheimer’s disease. Nearly 20 years of research went into developing the vaccine, which uses the immune system to clear Alzheimer’s disease-related proteins from the brain. Lead researcher Dr. Howard Weiner joins the podcast to discuss the science behind the vaccine and how it could introduce new ways of treating other neurodegenerative diseases in the future.
Guest: Howard Weiner, MD, professor of neurology, Harvard Medical School, co-director, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital